Tango Therapeutics, Inc.

Tango Therapeutics, a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings over three decades of biopharmaceutical industry leadership, including deep expertise in oncology commercialization and corporate strategy. His appointment is expected to be invaluable as Tango advances vopimetostat, its investigational PRMT5 inhibitor, towards potential late-stage development for pancreatic cancer.

Tango Therapeutics entered into an underwriting agreement for a public offering of 18,166,667 shares of common stock and 1,833,395 pre-funded warrants. The offering is expected to generate approximately $566.5 million in net proceeds. The company plans to use these funds for general corporate purposes, including research and development, pivotal trials, and potential commercialization, extending its cash runway into 2030.

Tango Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering expected to generate approximately $600 million in gross proceeds. The offering includes 18,166,667 shares of common stock priced at $30.00 per share and pre-funded warrants for up to 1,833,395 shares at $29.999 each. The company has also granted the underwriters a 30-day option to purchase an additional 3,000,009 shares of common stock.

Tango Therapeutics, a clinical-stage biotechnology company, announced the launch of an underwritten public offering to sell $500 million of its common stock. The company also intends to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares. J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there is no assurance regarding its completion, actual size, or terms.

Tango Therapeutics, Inc. announced positive initial safety and efficacy data from its Phase 1/2 combination trial evaluating vopimetostat with Revolution Medicines' RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The combination of vopimetostat and daraxonrasib demonstrated a 92% objective response rate (ORR) and a 90% six-month progression-free survival (PFS) rate in PDAC patients. The combination of vopimetostat and zoldonrasib showed a 52% ORR and a 74% six-month PFS rate in PDAC patients. Based on these results, Tango plans to advance the vopimetostat plus daraxonrasib combination into Phase 3 development for front-line pancreatic cancer.

Tango Therapeutics announced positive initial data from its Phase 1/2 study of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors for MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The vopimetostat plus daraxonrasib combination showed a 90% 6-month progression-free survival (PFS) rate and a 92% objective response rate (ORR) in PDAC patients, with both combinations being generally well-tolerated. These compelling results support the company's plan to rapidly advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer.

Tango Therapeutics announced that its Compensation Committee granted a non-qualified stock option to purchase 170,000 shares and 40,000 restricted stock units (RSUs) to a new employee. These awards were made effective June 1, 2026, under the company's 2023 Inducement Plan, which is used for equity awards to new hires. The options have an exercise price of $23.10 per share and both awards are subject to specific vesting schedules and continued employment.

Tango Therapeutics reported a Q1 2026 net loss of $45.5 million, or $0.32 per share, with $379.8 million in cash, cash equivalents, and marketable securities, providing a runway into 2028. Concurrently, Alexis Borisy and Kanishka Pothula resigned from the Board of Directors, and Sung Lee was appointed Lead Independent Director and Chairperson of the Compensation Committee. The company also provided positive updates on its vopimetostat clinical program, with initial Phase 1/2 data anticipated in 2026, and announced new key leadership appointments.

Tango Therapeutics reported a net loss of $(45.5) million for the first quarter of 2026, an increase from $(39.9) million in the same period last year, with collaboration revenue dropping to zero. Despite the increased loss, the company significantly strengthened its liquidity, with cash, cash equivalents, and marketable securities totaling $379.8 million as of March 31, 2026, extending its cash runway into 2028. This was largely due to $62.8 million raised from at-the-market offerings during the quarter. The company also outlined several upcoming clinical milestones for 2026, including initial Phase 1/2 data disclosures for vopimetostat and TNG456, and the initiation of a new combination trial.

Tango Therapeutics formalized the separation of its former Chief Financial Officer, Daniella Beckman, through a Separation Agreement and Release dated May 7, 2026. Ms. Beckman ceased her role on April 15, 2026. Under the agreement, she will receive 12 months of severance pay, 12 months of COBRA premium reimbursement, and accelerated vesting of certain equity awards, in exchange for a general release.